Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock
06 6월 2023 - 6:30AM
Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology
automation solutions for multi-omic and synthetic biology
applications, today announced the closing of its private placement
of redeemable convertible preferred stock and warrants resulting in
initial gross proceeds of $28.0 million to Telesis Bio. The
warrants issued in the private placement will provide Telesis Bio
with approximately $46.2 million in additional gross proceeds if
they are cash exercised.
The financing was led by Novalis LifeSciences
LLC with participation from Northpond Ventures, BroadOak Capital
Partners and M-185 Corporation, an affiliate of the Company’s Chief
Executive Officer and Founder, Todd R. Nelson, PhD.
The Company also announced the appointment of
Paul Meister, a partner at Novalis LifeSciences LLC, to the
Company’s board of directors immediately following the closing.
Please refer to the Company’s Form 8-K to be
filed with the Securities and Exchange Commission for the complete
terms of the financing.
The Company intends to use the proceeds from the
financing for general corporate purposes.
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER
TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITY. THE
SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND
MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR ANY STATE
THEREOF ABSENT REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE
STATE SECURITIES LAWS OR AN APPLICABLE EXEMPTION FROM REGISTRATION
REQUIREMENTS.
H.C. Wainwright & Co. acted as a financial
advisor for the private placement.
About Telesis Bio
Telesis Bio is empowering scientists with the
ability to create novel, synthetic biology-enabled solutions for
many of humanity’s greatest challenges. As inventors of the
industry-standard Gibson Assembly® method and the first commercial
automated benchtop DNA and mRNA synthesis system, Telesis Bio is
enabling rapid, accurate and reproducible writing of DNA and mRNA
for numerous downstream markets. The award-winning BioXp® system
consolidates, automates, and optimizes the entire synthesis,
cloning and amplification workflow. As a result, it delivers
virtually error-free synthesis of DNA and RNA at scale within days
and hours instead of weeks or months. Scientists around the world
are using the technology in their own laboratories to accelerate
the design-build-test paradigm for novel, high-value products for
precision medicine, biologics drug discovery, vaccine and
therapeutic development, genome editing, and cell and gene therapy.
Telesis Bio is a public company based in San Diego. For more
information, visit www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp
are trademarks of Telesis Bio Inc.
About Novalis LifeSciences
Novalis LifeSciences is a boutique investment
and advisory firm for the Life Science industry. With a team of
experienced operating executives from the industry, Novalis funds
and advises visionary Life Science entrepreneurs. For more
information visit www.novalislifesciences.com.
Forward-Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical
facts contained herein are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements include statements and
guidance regarding the anticipated use of proceeds from the
financing, as well as statements regarding the future release and
success of new and existing products and services. Such statements
are based on current assumptions that involve risks and
uncertainties that could cause actual outcomes and results to
differ materially. These risks and uncertainties, many of which are
beyond our control, include risks described in the section entitled
Risk Factors and elsewhere in our Annual Report on Form 10-K, which
was filed with the Securities and Exchange Commission (SEC) on
March 22, 2023, as amended on May 17, 2023 and in our Quarterly
Report on Form 10-Q, which was filed with the SEC on May 12, 2023.
These forward-looking statements speak only as of the date hereof
and should not be unduly relied upon. Telesis Bio disclaims any
obligation to update these forward-looking statements.
Contact:Jen CarrollVice President of Investor
Relationsjen.carroll@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Telesis Bio (NASDAQ:TBIO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024